drugset / Trial / NCT04838704
Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation
Completed
215 enrolled
Zhejiang University
Ruijin Hospital · collabThe Children's Hospital of Zhejiang University School of Medicine · collabThe First Affiliated Hospital of Zhengzhou University · collabYinzhou Hospital Affiliated to Medical School of Ningbo University · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Low Dose Ruxolitinib with Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor plus Methotrexate and Mycophenolate mofetil as Graft Versus Host Disease prophylaxis for HLA-haploidentical hematopoietic stem cell transplantation in low-dose antithymocyte globulin (ATG) system.
Timeline
- Start
- 2021-04-01
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mycophenolate Mofetil | Small molecule | — | — |
| Subject | Ruxolitinib | Small molecule | — | — |
| Comparator | Methotrexate | Small molecule | — | — |